Johnson & Johnson projects earnings impact from CAR-T deal
Sundry Photography/iStock Editorial via Getty Images
The Janssen unit of Johnson & Johnson (NYSE:JNJ) announced Tuesday that its parent company will incur a ~10c annual negative impact on 2023 and 2024 earnings per share as a result of a deal with Cellular Biomedicine Group (CBMG) for CAR T-cell therapies.
However, the company maintained its 2023 guidance and noted that the negative impact would primarily hurt its financials for Q2 2023, when the transaction is expected to close.
The CD20-directed autologous CAR-Ts that Janssen licenses from CBMG have indicated favorable overall and complete response rates in Phase 1 studies for patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) in China.
Per the terms, Janssen will receive a worldwide license to develop and commercialize the chimeric antigen receptor (CAR) T-cell candidates targeted at B-cell malignancies for markets outside Greater China.
In return, CBMG is entitled to an upfront payment of $245M from Janssen which will recognize the amount as a research and development expense during Q2.
There will also be future payments linked to development, regulatory, and sales milestones and tiered royalty payments based on net trade sales, excluding China.